Ixekizumab

• Plaque psoriasis (moderate-to-severe)
• Psoriatic arthritis
• Ankylosing spondylitis
• Non-radiographic axial spondyloarthritis
• Pediatric plaque psoriasis (ages 6+)

Ixekizumab (brand name Taltz) is a humanized IgG4 monoclonal antibody that selectively binds interleukin-17A (IL-17A), a central cytokine in the pathogenesis of psoriatic disease and several spondyloarthropathies. It is approved for moderate-to-severe plaque psoriasis in adults and pediatric patients aged 6 and older, active psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Delivered as a subcutaneous injection, it is notable for the rapid onset of skin clearance often seen within the first few weeks of treatment, with many patients achieving substantial or complete clearance by week 12. It belongs to a broader class of IL-17 pathway inhibitors that has reshaped management of moderate-to-severe psoriatic disease over the past decade.

Mechanism of Action

Interleukin-17A is produced primarily by Th17 cells and acts on keratinocytes and synovial cells to drive epidermal hyperproliferation and joint inflammation. The IL-23/Th17/IL-17 axis sits at the center of psoriasis pathogenesis: IL-23 from dendritic cells maintains Th17 cells, which release IL-17A to act on tissue. Ixekizumab neutralizes IL-17A by binding the cytokine and preventing engagement with the IL-17 receptor complex. This selective blockade reduces downstream production of inflammatory mediators including beta-defensins, S100 proteins, and chemokines that recruit neutrophils into psoriatic plaques and inflamed entheses (the connective tissue insertions central to spondyloarthropathy). Because IL-17A inhibition spares the broader immune response involved in viral and many bacterial defenses, infection risk is lower than with broader immunosuppressants such as TNF inhibitors or JAK inhibitors. Mucocutaneous candidiasis is more common, however, because IL-17 plays a key role in fungal mucosal defense. The FDA prescribing information details the full pharmacology.

Clinical Use

Ixekizumab is generally selected for patients with moderate-to-severe plaque psoriasis who have failed or cannot tolerate phototherapy, methotrexate, or apremilast. It is also a strong option for psoriatic arthritis, where it improves joint counts, skin clearance, enthesitis, and dactylitis simultaneously. Within the IL-17 inhibitor class, it competes with secukinumab and brodalumab; the choice often comes down to dosing schedule, payer coverage, prior treatment history, and clinician familiarity. For patients with concurrent inflammatory bowel disease such as ulcerative colitis or Crohn's disease, an IL-17 blocker is generally avoided in favor of an IL-23 inhibitor such as guselkumab or risankizumab, or a TNF inhibitor such as adalimumab, since IL-17 inhibition can paradoxically worsen colitis in susceptible patients. Spinal involvement, including inflammatory arthritis of the axial skeleton, responds well, with reductions in inflammation visible on MRI and clinical improvement in morning stiffness and back pain. The American College of Rheumatology guidelines outline current placement of IL-17 inhibitors in treatment algorithms for both psoriatic arthritis and spondyloarthritis.

How to Take It

Ixekizumab comes as an 80 mg/mL prefilled autoinjector or syringe. The plaque psoriasis induction schedule is 160 mg (two 80 mg injections) at week 0, then 80 mg at weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks for maintenance. Psoriatic arthritis and axial spondyloarthritis use 160 mg at week 0 followed by 80 mg every 4 weeks. Allow the device to warm at room temperature for about 30 minutes before injection to reduce stinging, and rotate sites between the front of the thigh, abdomen (avoiding the area around the navel), and the back of the upper arm. Avoid injecting into psoriatic plaques, tender or hard skin, scars, or stretch marks. Store unused devices in the refrigerator at 36-46 degrees F; once removed, use within five days and do not refrigerate again. The autoinjector takes about 10 seconds to deliver the dose; you will hear a click at the start and another at completion. If a dose is missed, administer it as soon as possible and resume the schedule from that date.

Monitoring and Follow-Up

Before starting, screen for latent tuberculosis with an interferon-gamma release assay or PPD, and review hepatitis B and C status. Routine pretreatment labs typically include CBC, comprehensive metabolic panel, and lipid profile, as discussed in our lab panels article. During therapy, periodic clinical reassessment focuses on skin clearance (using PASI or BSA scoring), joint counts in psoriatic arthritis, infection symptoms, and any new gastrointestinal complaints that could suggest emerging IBD. Annual TB screening is reasonable for patients in higher-risk settings, including those with significant travel exposure or known contacts. Vaccination status should be reviewed before initiation; live vaccines such as MMR, varicella, and yellow fever are contraindicated during treatment, while inactivated vaccines including annual influenza, pneumococcal, and the recombinant zoster vaccine are encouraged. Surveillance for nonmelanoma skin cancer with annual full skin exams is sensible, particularly for patients with prior phototherapy or significant cumulative sun exposure.

Special Populations

Pediatric dosing for plaque psoriasis is weight-based for ages 6 and older, with the same general schedule. In pregnancy, ixekizumab crosses the placenta, particularly in the third trimester via active IgG transport; exposure data are accumulating but remain limited, and the decision to continue should weigh disease severity against theoretical infant risk. Some clinicians stop biologics by gestational week 30-32 to minimize fetal exposure, although this should be individualized. Breastfeeding data are minimal, but the molecular size of IgG antibodies suggests low oral bioavailability in the infant and most authorities consider it likely compatible. No dose adjustment is needed for renal or hepatic impairment because the antibody is cleared by catabolism rather than these organs. Older adults tolerate the medication similarly to younger patients in trials, though infection vigilance should remain high. Patients with a history of recurrent oral or genital candidiasis should be counseled about increased risk and prompt treatment.

Long-Term Outcomes and Combination Therapy

Ixekizumab has shown durable response over multi-year extension studies, with most patients who achieve clear or almost clear skin maintaining that response with continued every-4-week dosing. Loss of response over time is uncommon but can occur, sometimes managed by escalating dosing frequency to every 2 weeks or switching to a different mechanism class. For patients with psoriatic arthritis, combination with methotrexate is sometimes used to enhance joint response or reduce immunogenicity, though IL-17 inhibitors are less prone to anti-drug antibody formation than TNF inhibitors. Topical therapies such as topical corticosteroids, vitamin D analogs, or tretinoin topical for adjunctive areas may continue to be useful for residual lesions even after substantial systemic clearance. Cardiovascular comorbidity is increased in psoriasis and psoriatic arthritis, and effective systemic therapy may improve cardiovascular biomarkers, though direct cardiovascular outcome trials are limited. Lipid management with statins, blood pressure control, smoking cessation, and weight management remain essential and are discussed in our heart-healthy habits article. Mental health screening for depression and anxiety, common in moderate-to-severe psoriasis, should be part of regular follow-up. Patients planning surgery should discuss perioperative biologic management with their surgeon and rheumatologist or dermatologist; many clinicians hold the dose so the next planned dose falls 1-2 weeks after surgery to balance infection risk with disease flare risk. Travel to areas with endemic infections such as tuberculosis, fungal disease, or hepatitis B requires pretrip planning and possibly avoidance of high-risk regions. Patients should carry a wallet card or other documentation listing the biologic for emergency situations or unexpected hospitalizations.

When to Contact Your Doctor

Call promptly for fever, chills, persistent cough, or other signs of infection, particularly tuberculosis or invasive fungal disease. New or worsening abdominal pain, diarrhea, blood in the stool, or unintended weight loss may signal new-onset or flaring inflammatory bowel disease and require evaluation. Severe injection-site reactions, hives, swelling of the face or throat, or wheezing constitute a medical emergency. Persistent oral or vaginal candidiasis, esophageal symptoms with painful swallowing, or skin fungal infections that do not clear with topical treatment warrant a check-in. Worsening of psoriasis on therapy or new joint symptoms also warrant a review to confirm the regimen still fits or whether secondary loss of response has occurred.

To discuss whether a biologic such as ixekizumab is right for your psoriatic disease, contact us or schedule a visit.